Cargando…

Multipotent luminal mammary cancer stem cells model tumor heterogeneity

INTRODUCTION: The diversity of human breast cancer subtypes has led to the hypothesis that breast cancer is actually a number of different diseases arising from cells at various stages of differentiation. The elusive nature of the cell(s) of origin thus hampers approaches to eradicate the disease. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Lei, Cardiff, Robert D., Steinbach, Paul, Messer, Karen S., Ellies, Lesley G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606989/
https://www.ncbi.nlm.nih.gov/pubmed/26467658
http://dx.doi.org/10.1186/s13058-015-0615-y
_version_ 1782395449870647296
author Bao, Lei
Cardiff, Robert D.
Steinbach, Paul
Messer, Karen S.
Ellies, Lesley G.
author_facet Bao, Lei
Cardiff, Robert D.
Steinbach, Paul
Messer, Karen S.
Ellies, Lesley G.
author_sort Bao, Lei
collection PubMed
description INTRODUCTION: The diversity of human breast cancer subtypes has led to the hypothesis that breast cancer is actually a number of different diseases arising from cells at various stages of differentiation. The elusive nature of the cell(s) of origin thus hampers approaches to eradicate the disease. METHODS: Clonal cell lines were isolated from primary transgenic polyomavirus middle T (PyVmT) luminal tumors. Mammary cancer stem cell (MaCSC) properties were examined by immunofluorescence, flow cytometry, differentiation assays and in vivo tumorigenesis. RESULTS: Clonal cell lines isolated from primary PyVmT mouse mammary luminal tumors can differentiate into luminal, myoepithelial, alveolar and adipocyte lineages. Upon orthotopic injection, progeny of a single cell follow a pattern of progression from ductal carcinoma in situ, to adenoma, adenocarcinoma and epithelial metastasis that recapitulates the transgenic model. Tumors can evolve in vivo from hormone receptor-positive to hormone receptor-negative Her2-positive, or triple negative CD44hi basal-like and claudin-low tumors. Contrary to the current paradigm, we have defined a model in which multiple tumor subtypes can originate from a single multipotent cancer stem cell that undergoes genetic and/or epigenetic evolution during tumor progression. As in human tumors, the more aggressive tumor subtypes express nuclear p53. Tumor cell lines can also be derived from these more advanced tumor subtypes. CONCLUSIONS: Since the majority of human tumors are of the luminal subtype, understanding the cell of origin of these tumors and how they relate to other tumor subtypes will impact cancer therapy. Analysis of clonal cell lines derived from different tumor subtypes suggests a developmental hierarchy of MaCSCs, which may provide insights into the progression of human breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0615-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4606989
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46069892015-10-16 Multipotent luminal mammary cancer stem cells model tumor heterogeneity Bao, Lei Cardiff, Robert D. Steinbach, Paul Messer, Karen S. Ellies, Lesley G. Breast Cancer Res Research Article INTRODUCTION: The diversity of human breast cancer subtypes has led to the hypothesis that breast cancer is actually a number of different diseases arising from cells at various stages of differentiation. The elusive nature of the cell(s) of origin thus hampers approaches to eradicate the disease. METHODS: Clonal cell lines were isolated from primary transgenic polyomavirus middle T (PyVmT) luminal tumors. Mammary cancer stem cell (MaCSC) properties were examined by immunofluorescence, flow cytometry, differentiation assays and in vivo tumorigenesis. RESULTS: Clonal cell lines isolated from primary PyVmT mouse mammary luminal tumors can differentiate into luminal, myoepithelial, alveolar and adipocyte lineages. Upon orthotopic injection, progeny of a single cell follow a pattern of progression from ductal carcinoma in situ, to adenoma, adenocarcinoma and epithelial metastasis that recapitulates the transgenic model. Tumors can evolve in vivo from hormone receptor-positive to hormone receptor-negative Her2-positive, or triple negative CD44hi basal-like and claudin-low tumors. Contrary to the current paradigm, we have defined a model in which multiple tumor subtypes can originate from a single multipotent cancer stem cell that undergoes genetic and/or epigenetic evolution during tumor progression. As in human tumors, the more aggressive tumor subtypes express nuclear p53. Tumor cell lines can also be derived from these more advanced tumor subtypes. CONCLUSIONS: Since the majority of human tumors are of the luminal subtype, understanding the cell of origin of these tumors and how they relate to other tumor subtypes will impact cancer therapy. Analysis of clonal cell lines derived from different tumor subtypes suggests a developmental hierarchy of MaCSCs, which may provide insights into the progression of human breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0615-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-14 2015 /pmc/articles/PMC4606989/ /pubmed/26467658 http://dx.doi.org/10.1186/s13058-015-0615-y Text en © Bao et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0 (http://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bao, Lei
Cardiff, Robert D.
Steinbach, Paul
Messer, Karen S.
Ellies, Lesley G.
Multipotent luminal mammary cancer stem cells model tumor heterogeneity
title Multipotent luminal mammary cancer stem cells model tumor heterogeneity
title_full Multipotent luminal mammary cancer stem cells model tumor heterogeneity
title_fullStr Multipotent luminal mammary cancer stem cells model tumor heterogeneity
title_full_unstemmed Multipotent luminal mammary cancer stem cells model tumor heterogeneity
title_short Multipotent luminal mammary cancer stem cells model tumor heterogeneity
title_sort multipotent luminal mammary cancer stem cells model tumor heterogeneity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606989/
https://www.ncbi.nlm.nih.gov/pubmed/26467658
http://dx.doi.org/10.1186/s13058-015-0615-y
work_keys_str_mv AT baolei multipotentluminalmammarycancerstemcellsmodeltumorheterogeneity
AT cardiffrobertd multipotentluminalmammarycancerstemcellsmodeltumorheterogeneity
AT steinbachpaul multipotentluminalmammarycancerstemcellsmodeltumorheterogeneity
AT messerkarens multipotentluminalmammarycancerstemcellsmodeltumorheterogeneity
AT ellieslesleyg multipotentluminalmammarycancerstemcellsmodeltumorheterogeneity